Entrada Therapeutics (NASDAQ:TRDA) Director Bernhardt Zeiher Acquires 5,000 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Bernhardt Zeiher acquired 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $5.86 per share, for a total transaction of $29,300.00. Following the completion of the acquisition, the director owned 5,000 shares of the company’s stock, valued at $29,300. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Entrada Therapeutics Stock Up 4.5%

TRDA stock traded up $0.27 during trading on Thursday, hitting $6.31. 371,925 shares of the company’s stock traded hands, compared to its average volume of 307,525. The firm has a market capitalization of $244.95 million, a P/E ratio of -1.58 and a beta of -0.09. The business has a fifty day simple moving average of $11.80 and a two-hundred day simple moving average of $10.89. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.11. The company had revenue of $0.88 million for the quarter, compared to analyst estimates of $2.92 million. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. On average, equities research analysts predict that Entrada Therapeutics, Inc. will post -4.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Entrada Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC acquired a new stake in shares of Entrada Therapeutics during the first quarter worth $385,000. The Manufacturers Life Insurance Company lifted its stake in shares of Entrada Therapeutics by 25.0% during the first quarter. The Manufacturers Life Insurance Company now owns 70,656 shares of the company’s stock worth $892,000 after buying an additional 14,111 shares during the period. Quantinno Capital Management LP lifted its stake in shares of Entrada Therapeutics by 4.9% during the first quarter. Quantinno Capital Management LP now owns 71,018 shares of the company’s stock worth $896,000 after buying an additional 3,301 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Entrada Therapeutics by 18.7% during the first quarter. Dimensional Fund Advisors LP now owns 324,471 shares of the company’s stock worth $4,092,000 after buying an additional 51,093 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Entrada Therapeutics by 11.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 19,465 shares of the company’s stock worth $246,000 after buying an additional 1,970 shares during the period. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Wall Street Zen lowered shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Oppenheimer lifted their price target on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Finally, Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Entrada Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.25.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.